GLP-1 drugs expand to heart failure, addiction and aging trials
Original title: Ozempic-style drugs now in trials for heart failure, addiction and even aging
GLP-1 drugs like Ozempic are in trials for addiction, heart failure, and biological aging, with non-diabetes applications tripling in recent years.
ClinicalTrials.gov data shows GLP-1 and incretin drugs are tested in thousands of trials. Five in six target diabetes and weight loss, but the share for other diseases is growing rapidly. Trials cover addiction, heart failure, kidneys, liver, cancer, Alzheimer’s and aging. Most research remains focused on the original indications, but expansion continues across multiple disease areas.
- Share of non-diabetes trials rose from one in fourteen to one in four
- Addiction trials lead the expansion
- Semaglutide tested for alcohol use disorder and Alzheimer’s
- Count includes at least 1,800 registered human studies
From the original article
5 min read at maccus.fr
The diabetes drugs that became weight-loss blockbusters are now in human trials for heart failure, addiction, Alzheimer’s and even the biology of aging. Most of that research is still about diabetes and weight, about five in six of the trials. The change is how fast the rest is growing.
By randycupertino · maccus.fr
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.